- Home
- ACRE vs FENC Comparison
ACRE vs FENC Comparison
Compare ACRE & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | FENC |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 230.8M |
| IPO Year | 2011 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ACRE | FENC |
|---|---|---|
| Price | $4.88 | $11.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $5.38 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 512.9K | 132.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | 0.01 |
| Revenue | ★ $54,833,000.00 | $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | $16.28 | $41.08 |
| P/E Ratio | ★ $3.61 | $1,157.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.14 | $5.65 |
| 52 Week High | $5.89 | $11.66 |
Technical Indicators
Market Signals| Indicator | ACRE | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 60.06 |
| Support Level | $4.67 | $9.91 |
| Resistance Level | $5.06 | $11.28 |
| Average True Range (ATR) | 0.14 | 0.60 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 81.43 | 92.92 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.